Parkinson's disease: in vivo assessment of disease progression using positron emission tomography

Wing Lok Au; John R Adams; André R Troiano; A Jon Stoessl

doi:10.1016/j.molbrainres.2004.09.028

Parkinson's disease: in vivo assessment of disease progression using positron emission tomography

Brain Res Mol Brain Res. 2005 Mar 24;134(1):24-33. doi: 10.1016/j.molbrainres.2004.09.028. Epub 2004 Nov 2.

Authors

Wing Lok Au¹, John R Adams, André R Troiano, A Jon Stoessl

Affiliation

¹ Pacific Parkinson's Research Centre, University of British Columbia, Vancouver Hospital and Health Sciences Centre, Purdy Pavilion, 2221 Wesbrook Mall, Vancouver, BC, Canada V6T 2B5.

PMID: 15790527
DOI: 10.1016/j.molbrainres.2004.09.028

Abstract

Over the past two decades, positron emission tomography (PET) has provided valuable insights into the mechanisms of nigrostriatal degeneration in Parkinson's disease (PD). Furthermore, it allows the in vivo assessment of disease progression and the evaluation of treatment interventions. In this review, we shall discuss some of the issues and concerns that arise with the use of PET as a surrogate marker of disease progression in Parkinson's disease.

Publication types

Review

MeSH terms

Animals
Brain / diagnostic imaging*
Disease Progression
Dopamine
Dopamine Plasma Membrane Transport Proteins
Humans
Membrane Glycoproteins
Membrane Transport Proteins
Models, Neurological
Nerve Tissue Proteins
Parkinson Disease / diagnostic imaging*
Positron-Emission Tomography*
Vesicular Biogenic Amine Transport Proteins

Substances

Dopamine Plasma Membrane Transport Proteins
Membrane Glycoproteins
Membrane Transport Proteins
Nerve Tissue Proteins
Vesicular Biogenic Amine Transport Proteins
Dopamine